A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Trial Profile

A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Mar 2016 Status changed from planning to recruiting as reported by ClinicalTrials.gov.
    • 17 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top